Recent advances in the field of sleep medicine have led to an understanding of the underlying cause of narcolepsy, leading to a dramatic surge in the development of new investigational drugs. Several companies are now planning to head into clinic with studies of orexin receptor agonists as potential treatments for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and other related disorders.

Join Dr. Gary Zammit, President and CEO of Clinilabs Drug Development Corporation, as he discusses common pathways for clinical drug development in narcolepsy. Hear his discussion of the opportunities and challenges ahead as we race to bring forward new, safe, and effective treatments for narcolepsy.

Click here to register.